Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Share Buy-back Programme – Transactions Week 23
-
Sterling Trading Tech Implements Revised FINRA Rule 4210 for Lightspeed Financial
-
Anoto Group AB (publ) announces an increase in conversion price from SEK 0.06 to SEK 0.12 for a new USD 0.6 million tranche under its convertible loan facility.
-
Casino Group Communication
-
Amphista Therapeutics announces FDA clearance of IND application for AMX-883, its lead Targeted Glue™ degrader for acute myeloid leukaemia
-
Realtek Joins OpenTitan Coalition to Develop Discrete Hardware Root of Trust Devices
-
ING to appoint Andrea Cesaroni as chief risk officer
-
NBPE Announces Transaction in Own Shares
-
Copenhagen Infrastructure Partners partially divests 500MW Devilla BESS project to Scottish National Investment Bank and Nuclear Liabilities Fund
-
Transaction in Own Shares
-
Sterling Trading Tech Implements Revised FINRA Rule 4210 for Lightspeed Financial
-
Intravacc Highlights Integrated Analytical Capabilities to Accelerate Vaccine and Biologics Development
-
FLSmidth: Transactions under share buy-back programme
-
Bombardier and Elie Saab Debut First-of-its-kind Collaboration, Introducing the Haute Couture of Aviation with Bespoke Global 8000 Cabin Design
-
Rackspace Technology Establishes Regional Headquarters in Riyadh to Accelerate Cloud and AI Growth
-
Reminder: Nicox June 2024 Warrants will expire June 19, 2026
-
Sampo plc’s share buybacks week 23/2026
-
Thian Ong Financial Academy's Tan Thian Ong Interprets AI Technology Applications: Cross-Domain Collaboration Is the Key Driving Force
-
Thian Ong Financial Academy's Tan Thian Ong Interprets AI Technology Applications: Cross-Domain Collaboration Is the Key Driving Force
-
Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology
-
Start of Day Message
-
Press Release: Sanofi’s Sarclisa subcutaneous approved in the EU as the first anticancer treatment administered via an on-body injector
-
WISeKey, The Hashgraph Group and Hedera Launch QAIT Q-Day Security Assessment Platform on the SEALCOIN Quantum Marketplace
-
Nyrstar NV provides an update with regards to the Antwerp criminal investigation
-
Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurology
-
Aktsiaselts Infortar own share acquisition transactions
-
Vivoryon Therapeutics N.V. to Report Q1 2026 Financial Results on June 11, 2026
-
IBA signs contract with a major U.S. academic medical center to install two Proteus®ONE proton therapy solutions
-
TGS Acquires Apparition Geoservices to Deliver a Step-Change in Seismic Efficiency and Subsurface Imaging
-
Toobit Adds XLM to Fixed Earn Series with Limited-Time 60% APR
-
Rumble Announces Final Results of Exchange Offer for Northern Data
-
Lim Meng Hoong: AI Is Entering a New Era of Scientific Infrastructure, Insights from Science x AI Summit 2026
-
Macau Tea Beverage Brand 'Cha Yu' Redefines Local Flavors with Original Recipes and Signature Cloud Milk Tea
-
Solidion Technology Announces $35 Million Private Placement of Common Stock Priced Above Market Under Nasdaq Rules
-
GNI Group to Acquire Ayumi Pharmaceutical Holdings, Expanding Its Position as a Global Biopharmaceutical Company
-
LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China
-
Odysight.ai® Establishes At-The-Market (ATM) Program of up to $20 Million to Enhance Financial Flexibility
-
NAVER Expands AI Infrastructure With NVIDIA to Serve Surging Global AI Demand
-
NVIDIA and SK hynix Announce Multiyear Technology Partnership to Advance Memory for AI Factories
-
SK Telecom and NVIDIA Build AI Infrastructure to Power Korea’s AI Innovation
-
Entrata Collaborates with OpenAI to Define the Future of Autonomous Property Management
-
Diasome Presents Phase 2b Data Demonstrating HDV™-Insulin Lispro Maintains Glycemic Control While Reducing Hypoglycemia in Adults with Type 1 Diabetes
-
Canadian Employers Invited to Create 10,000 New Opportunities Through National Inclusive Hiring Campaign
-
GoHealth, Inc. to strengthen its position ahead of AEP 2026 through Restructuring Process supported by key stakeholders
-
Zealand Pharma announces Boehringer Ingelheim's survodutide Phase III trial in people living with obesity showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss
-
Zealand Pharma announces Boehringer Ingelheim's survodutide Phase III trial in people living with obesity showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in p
-
Boehringer Ingelheim’s survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis, supporting improved metabolic
-
Antag Therapeutics presents positive Phase 1 results at the 2026 Scientific Sessions of the American Diabetes Association for AT7687, a first-in-class GIPR antagonist
-
CREDIT AGRICOLE S.A. ANNOUNCES REDEMPTION OF ¥84,200,000,000 Japanese Yen Callable Senior Non-Preferred Bonds issued on June 3, 2021 (ISIN: JP525022AM69)
-
Casino Group Communication
